Platelet FcɣRIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction
Catheterization and Cardiovascular Interventions · 2026
DOI: 10.1002/ccd.70691 ↗Kurz gefasst
Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, 2026. Verfasst von David J Schneider und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Cardiovascular Research Institute, The University of Vermont, Burlington, Vermont, USA. Hauptthemen laut MEDLINE: Blood Platelets, Myocardial Infarction, Receptors, IgG, Flow Cytometry. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prolocor Inc.
Abstract (Originalsprache)
Background
In patients with myocardial infarction (MI), quantifying expression of platelet FcɣRIIa (pFCG) stratifies risk of subsequent MI, stroke, and death.
Aims
Assess the prognostic implications of clinical risk alone and in combination with the pFCG test.
Methods
Patients ( n = 749) were enrolled in a prospective non‐interventional trial during hospitalization with type 1 MI (ST elevation and non‐ST elevation). Inclusion criteria included ≥ 2 of the following clinical risk factors: age ≥ 65, multi‐vessel coronary artery disease, prior MI, chronic kidney disease, or diabetes mellitus. High and low pFCG (quantified by flow cytometry at a core laboratory) were defined by a prespecified threshold. The primary endpoint was the composite of MI, stroke, and death.
Results
Distribution of clinical risk factors was 346 patients (45%) with 2 factors, 272 patients (36%) with 3 factors, and 131 patients (17%) with 4 or 5 factors. A greater number of risk factors was associated with a greater risk of the composite of MI, stroke, and death after 1 year. The event rate with 2 risk factors was 10.2%, with 3 factors it was 14.4%, and with 4/5 factors it was 35.6%. Across all cohorts of clinical risk, the pFCG test identified a higher‐risk and a lower‐risk cohort.
Conclusions
Both clinical risk and the pFCG test assess prognosis. Results of the pFCG test refine the prognosis defined by clinical risk. The prognostic implications suggest that the pFCG test may be a useful tool to balance ischemic risk with that of bleeding to define treatment strategy. Clinical Trial Registration https://clinicaltrials.gov/study/NCT05175261 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Cardiovascular Research Institute, The University of Vermont, Burlington, Vermont, USA.
- Department of Medicine, Hartford Hospital, Hartford, Connecticut, USA.
- Department of Medicine, Division of Cardiology, University of Florida, Jacksonville, Florida, USA.
- Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Adventist Healthcare White Oak, Silver Spring, Maryland, USA.
- Division of Cardiovascular Medicine, Maine Medical Center, Portland, Maine, USA.
ORCID-Profile: Peter M DiBattiste
Förderung
- Prolocor Inc
Zitieren
APA
Schneider, D. J., McMahon, S. R., Angiolillo, D. J., Fanaroff, A. C., Ibrahim, H., Hohl, P. K., Wanamaker, B. L., Effron, M. B., DiBattiste, P. M., & behalf of the investigators (2026). Platelet FcɣRIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70691
Vancouver
Schneider DJ, McMahon SR, Angiolillo DJ, Fanaroff AC, Ibrahim H, Hohl PK, et al. Platelet FcɣRIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction. Catheterization and Cardiovascular Interventions. 2026. doi:10.1002/ccd.70691
BibTeX
@article{Schneider2026,
author = {Schneider, David J and McMahon, Sean R and Angiolillo, Dominick J and Fanaroff, Alexander C and Ibrahim, Homam and Hohl, Patrick K and Wanamaker, Brett L and Effron, Mark B and DiBattiste, Peter M and behalf of the investigators, behalf of the investigators},
title = {Platelet FcɣRIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
doi = {10.1002/ccd.70691}
}
EUVIMED